Detorubicin hydrochloride  (Synonyms: NSC 292652 hydrochloride; RP 33921 hydrochloride)

Detorubicin hydrochloride (NSC 292652 hydrochloride) is a semi-synthetic analog of Daunorubicin (HY-13062A) and a prodrug of Doxorubicin (HY-15142A). Detorubicin hydrochloride hydrolyzes to release Doxorubicin under neutral pH conditions. Detorubicin hydrochloride forms complexes with DNA. Detorubicin hydrochloride exhibits anti-hematologic tumor and metastatic melanoma activities. Detorubicin hydrochloride causes myocardial injury, skin damage, alopecia, and high mortality in golden hamsters. Detorubicin hydrochloride can be used in research related to leukemia, and metastatic melanoma^[1][2][3][4].

Detorubicin (20-120 min) shows pH-dependent stability in cell-free solutions, with the highest stability at pH 4.5 (half-life 600 min), intermediate stability at pH 6.5 (half-life 24 min), and lowest stability at pH 7.4 (half-life 4.6 min)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Detorubicin hydrochloride shows greater potency than doxorubicin against subcutaneously inoculated L1210 murine leukemia^[1].
Detorubicin (3 mg/kg; i.p.; three times a week; up to 4 weeks) hydrochloride causes 100% mortality in golden hamsters, alongside severe myocardial ultrastructural damage and degenerative skin lesions with alopecia^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

710.12

C₃₃H₄₀ClNO₁₄

64291-45-8

OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(COC(C(OCC)OCC)=O)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zenebergh A, et al. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells. European journal of cancer & clinical oncology. 1984 Jan;20(1):115-21.  [Content Brief]

  [2]. Chawla SP, et al. Detorubicin--an active anthracycline in untreated metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1985 Nov;3(11):1529-34.  [Content Brief]

  [3]. Trouet A, et al. Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data. Cancer Chemother Pharmacol. 1979;2(1):77-9.  [Content Brief]

  [4]. Dantchev D, et al. Ultrastructural study of the cardiotoxicity and light-microscopic findings of the skin after treatment of golden hamsters with seven different anthracyclines. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 1980;74:223-49.  [Content Brief]